Loading...
Corcept Therapeutics Community
NasdaqCM:CORT Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 114 Fair Values set on narratives written by author
Community Investing Ideas
Patient Screening And Regulatory Approvals Will Unlock Global Markets
Key Takeaways Expanding disease awareness, anticipated drug approvals, and enhanced commercial operations are set to propel revenue growth and decrease reliance on a single product. Favorable demographic trends and proven regulatory execution support ongoing market and earnings expansion for the company.Read more
0users have liked this narrative
0users have commented on this narrative
57users have followed this narrative
AN
US$134.5
45.2% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
40.67% p.a.
Profit Margin
37.28%
Future PE
23.58x
Share price in 2028
US$163.46